{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:05:27Z","timestamp":1793919927380,"version":"4.8.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novartis Pharma AG, Basel, Switzerland"},{"DOI":"10.13039\/501100001652","name":"Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001652","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40257-023-00782-8","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T12:02:26Z","timestamp":1687348946000},"page":"821-835","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials"],"prefix":"10.1007","volume":"24","clinical-trial-number":[{"clinical-trial-number":"nct03668613","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02471144","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9396-3938","authenticated-orcid":false,"given":"Michael","family":"Sticherling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjen F.","family":"Nikkels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf M.","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek C.","family":"Szepietowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahira","family":"El Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Dominique","family":"Ghislain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alkes A.","family":"Khotko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manmath","family":"Patekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine-Elke","family":"Ortmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Forrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philemon","family":"Papanastasiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Keefe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"issue":"2","key":"782_CR1","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/pde.13382","volume":"35","author":"LF Eichenfield","year":"2018","unstructured":"Eichenfield LF, Paller AS, Tom WL, Sugarman J, Hebert AA, Friedlander SF, et al. Pediatric psoriasis: evolving perspectives. Pediatr Dermatol. 2018;35(2):170\u201381.","journal-title":"Pediatr Dermatol"},{"key":"782_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-90712-9","volume-title":"Pediatric psoriasis","author":"AB Fortina","year":"2022","unstructured":"Fortina AB, Caroppo F. Pediatric psoriasis. Berlin: Springer Nature; 2022."},{"key":"782_CR3","first-page":"45","volume":"10","author":"E Mahe","year":"2020","unstructured":"Mahe E. Optimal management of plaque psoriasis in adolescents: current perspectives. Psoriasis (Auckl). 2020;10:45\u201356.","journal-title":"Psoriasis (Auckl)."},{"issue":"6","key":"782_CR4","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.3892\/etm.2021.10864","volume":"22","author":"DE Branisteanu","year":"2021","unstructured":"Branisteanu DE, Georgescu S, Serban IL, Pinzariu AC, Boda D, Maranduca MA, et al. Management of psoriasis in children. Exp Ther Med. 2021;22(6):1429.","journal-title":"Exp Ther Med"},{"issue":"2","key":"782_CR5","first-page":"187","volume":"17","author":"AS Paller","year":"2018","unstructured":"Paller AS, Singh R, Cloutier M, Gauthier-Loiselle M, Emond B, Guerin A, et al. Prevalence of psoriasis in children and adolescents in the United States: a claims-based analysis. J Drugs Dermatol. 2018;17(2):187\u201394.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"782_CR6","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1590\/abd1806-4841.20186981","volume":"93","author":"A Salman","year":"2018","unstructured":"Salman A, Yucelten AD, Sarac E, Saricam MH, Perdahli-Fis N. Impact of psoriasis in the quality of life of children, adolescents and their families: a cross-sectional study. An Bras Dermatol. 2018;93(6):819\u201323.","journal-title":"An Bras Dermatol"},{"issue":"1","key":"782_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jaad.2019.05.056","volume":"82","author":"P Lansang","year":"2020","unstructured":"Lansang P, Bergman JN, Fiorillo L, Joseph M, Lara-Corrales I, Marcoux D, et al. Management of pediatric plaque psoriasis using biologics. J Am Acad Dermatol. 2020;82(1):213\u201321.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"782_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40272-015-0137-1","volume":"17","author":"IM Bronckers","year":"2015","unstructured":"Bronckers IM, Paller AS, van Geel MJ, van de Kerkhof PC, Seyger MM. Psoriasis in children and adolescents: diagnosis, management and comorbidities. Paediatr Drugs. 2015;17(5):373\u201384.","journal-title":"Paediatr Drugs"},{"issue":"3","key":"782_CR9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40272-022-00501-6","volume":"24","author":"J Zitouni","year":"2022","unstructured":"Zitouni J, Beauchet A, Curmin R, Di Lernia V, Bursztejn AC, Mazereeuw-Hautier J, et al. Effectiveness and safety of adalimumab, etanercept and ustekinumab for severe psoriasis in children under 12 years of age: a French-Italian daily practice cohort (BiPe Jr). Paediatr Drugs. 2022;24(3):281\u201392.","journal-title":"Paediatr Drugs"},{"issue":"6","key":"782_CR10","first-page":"AB178","volume":"83","author":"Y Goenaga-V\u00e1zquez","year":"2020","unstructured":"Goenaga-V\u00e1zquez Y, Lauck KC, Grabell D, Hebert AA. 16403 Therapeutic challenges in managing pediatric psoriasis. J Am Acad Dermatol. 2020;83(6):AB178.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"782_CR11","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s13555-022-00758-2","volume":"12","author":"K Peris","year":"2022","unstructured":"Peris K, Fortina AB, Bianchi L, Fabbrocini G, Gisondi P, Balato A, et al. Update on the management of pediatric psoriasis: an Italian consensus. Dermatol Ther (Heidelb). 2022;12(8):1753\u201375.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"6","key":"782_CR12","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/jdv.16124","volume":"34","author":"K Reich","year":"2020","unstructured":"Reich K, Warren RB, Coates LC, Di Comite G. Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. J Eur Acad Dermatol Venereol. 2020;34(6):1161\u201373.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"782_CR13","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1080\/09546634.2019.1626973","volume":"31","author":"A Pinter","year":"2020","unstructured":"Pinter A, Gerdes S, Papavassilis C, Reinhardt M. Characterization of responder groups to secukinumab treatment in moderate-to-severe plaque psoriasis. J Dermatol Treat. 2020;31(8):769\u201375.","journal-title":"J Dermatol Treat"},{"key":"782_CR14","unstructured":"Cosentyx PI U 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125504s043lbl.pdf. Accessed 01 May 2022."},{"key":"782_CR15","unstructured":"Cosentyx SmPC. 2021.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cosentyx-epar-product-information_en.pdf. Accessed 26 July 2021."},{"issue":"1","key":"782_CR16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jaad.2021.08.066","volume":"86","author":"N Magnolo","year":"2022","unstructured":"Magnolo N, Kingo K, Laquer V, Browning J, Reich A, Szepietowski JC, et al. A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results. J Am Acad Dermatol. 2022;86(1):122\u201330.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"782_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40272-022-00507-0","volume":"24","author":"N Magnolo","year":"2022","unstructured":"Magnolo N, Kingo K, Laquer V, Browning J, Reich A, Szepietowski JC, et al. Efficacy of secukinumab across subgroups and overall safety in pediatric patients with moderate to severe plaque psoriasis: week 52 results from a phase III randomized study. Paediatr Drugs. 2022;24(4):377\u201387.","journal-title":"Paediatr Drugs"},{"issue":"4","key":"782_CR18","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/jdv.17002","volume":"35","author":"C Bodemer","year":"2021","unstructured":"Bodemer C, Kaszuba A, Kingo K, Tsianakas A, Morita A, Rivas E, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial. J Eur Acad Dermatol Venereol. 2021;35(4):938\u201347.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"782_CR19","unstructured":"Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year (ERASURE). 2011. https:\/\/ClinicalTrials.gov\/show\/NCT01365455. Accessed 26 July 2021."},{"key":"782_CR20","unstructured":"Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE) 2012. https:\/\/ClinicalTrials.gov\/show\/NCT01636687. Accessed 26 July 2021."},{"key":"782_CR21","unstructured":"Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis (FIXTURE). 2011. https:\/\/ClinicalTrials.gov\/show\/NCT01358578. Accessed 26 July 2021."},{"key":"782_CR22","unstructured":"First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: response at 12 Weeks (FEATURE). 2012. https:\/\/ClinicalTrials.gov\/show\/NCT01555125. Accessed 26 July 2021."},{"issue":"7","key":"782_CR23","doi-asserted-by":"publisher","first-page":"486","DOI":"10.7326\/0003-4819-146-7-200704030-00004","volume":"146","author":"MM Hsieh","year":"2007","unstructured":"Hsieh MM, Everhart JE, Byrd-Holt DD, Tisdale JF, Rodgers GP. Prevalence of neutropenia in the US population: age, sex, smoking status, and ethnic differences. Ann Intern Med. 2007;146(7):486\u201392.","journal-title":"Ann Intern Med"},{"issue":"4","key":"782_CR24","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","volume":"73","author":"I Landells","year":"2015","unstructured":"Landells I, Marano C, Hsu MC, Li S, Zhu Y, Eichenfield LF, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73(4):594\u2013603.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"782_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","volume":"21","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):111.","journal-title":"Arthritis Res Ther"},{"key":"782_CR26","doi-asserted-by":"publisher","first-page":"adv00698","DOI":"10.2340\/actadv.v102.563","volume":"102","author":"AB Gottlieb","year":"2022","unstructured":"Gottlieb AB, Deodhar A, McInnes IB, Baraliakos X, Reich K, Schreiber S, et al. Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data. Acta Derm Venereol. 2022;102:adv00698.","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"782_CR27","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.4049\/jimmunol.157.8.3223","volume":"157","author":"DO Willenborg","year":"1996","unstructured":"Willenborg DO, Fordham S, Bernard CC, Cowden WB, Ramshaw IA. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol. 1996;157(8):3223\u20137.","journal-title":"J Immunol"},{"issue":"3","key":"782_CR28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.immuni.2005.01.011","volume":"22","author":"MA Stark","year":"2005","unstructured":"Stark MA, Huo Y, Burcin TL, Morris MA, Olson TS, Ley K. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity. 2005;22(3):285\u201394.","journal-title":"Immunity"},{"issue":"1","key":"782_CR29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","volume":"75","author":"PC van de Kerkhof","year":"2016","unstructured":"van de Kerkhof PC, Griffiths CE, Reich K, Leonardi CL, Blauvelt A, Tsai TF, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(1):83-98.e4.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"782_CR30","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/bjd.12744","volume":"170","author":"AB Kimball","year":"2014","unstructured":"Kimball AB, Schenfeld J, Accortt NA, Anthony MS, Rothman KJ, Pariser D. Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the USA: 2005\u201309. Br J Dermatol. 2014;170(2):366\u201373.","journal-title":"Br J Dermatol"},{"issue":"9","key":"782_CR31","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1007\/s11606-011-1698-5","volume":"26","author":"RV Patel","year":"2011","unstructured":"Patel RV, Shelling ML, Prodanovich S, Federman DG, Kirsner RS. Psoriasis and vascular disease\u2014risk factors and outcomes: a systematic review of the literature. J Gen Intern Med. 2011;26(9):1036\u201349.","journal-title":"J Gen Intern Med"},{"issue":"12","key":"782_CR32","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/jamadermatol.2018.3631","volume":"154","author":"Y Fu","year":"2018","unstructured":"Fu Y, Lee CH, Chi CC. Association of psoriasis with inflammatory bowel disease: a systematic review and meta-analysis. JAMA Dermatol. 2018;154(12):1417\u201323.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"782_CR33","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s13555-016-0139-0","volume":"6","author":"L Kircik","year":"2016","unstructured":"Kircik L, Fowler J, Weiss J, Meng X, Guana A, Nyirady J. Efficacy of secukinumab for moderate-to-severe head and neck psoriasis over 52 weeks: pooled analysis of four phase 3 studies. Dermatol Ther (Heidelb). 2016;6(4):627\u201338.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"4","key":"782_CR34","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014;371(4):326\u201338.","journal-title":"N Engl J Med"},{"issue":"6","key":"782_CR35","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/jdv.12751","volume":"29","author":"C Paul","year":"2015","unstructured":"Paul C, Lacour JP, Tedremets L, Kreutzer K, Jazayeri S, Adams S, et al. Efficacy, safety and usability of secukinumab administration by autoinjector\/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6):1082\u201390.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-023-00782-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-023-00782-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-023-00782-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T06:22:13Z","timestamp":1693030933000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-023-00782-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["782"],"URL":"https:\/\/doi.org\/10.1007\/s40257-023-00782-8","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]},"assertion":[{"value":"3 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL. The study was funded by Novartis Pharma AG, Basel, Switzerland.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"<i>Michael Sticherling<\/i> is an investigator, speaker, consultant\/advisory board member, and participated in clinical trials with the following companies: AbbVie, Amgen, BMS, Celgene, Galderma, GSK, Janssen Cilag, Leo, Lilly, MSD, Mundipharma, Novartis, Regeneron, Pfizer, Sanofi, and UCB. <i>Arjen F. Nikkels<\/i> has nothing to disclosure. <i>Ashraf M. Hamza<\/i> is a principal investigator for Novartis and speaker for Sanofi and Pfizer. <i>Pearl Kwong<\/i> is an investigator, speaker, and\/or consultant for Pfizer, Eli Lilly, Regeneron Sanofi Genzyme, Ortho, Verrica, Vyne, Journey, Incyte Almirall, Novartis, Amgen\/Celgene, AbbVie, Dermira, Galderma, Castle Creek Biosciences, and Arcutis. <i>Jacek C. Szepietowski<\/i> is an advisory board member of AbbVie, LEO Pharma, Novartis, Pierre-Fabre, Menlo Therapeutics, Sienna Biopharmaceuticals, and Trevi Therapeutics; principal investigator for AbbVie, Novartis, Menlo Therapeutics, Trevi Therapeutics, Janssen, Merck, Regeneron, Amgen, Boehringer Ingelheim, Galapagos, Galderma, InflaRX, Kymab Ltd., Pfizer, UCB, Helm, and Incyte; and a speaker for AbbVie, Novartis, Janssen, Eli Lilly, Sanofi-Genzyme, Sunfarm, and Berlin-Chemie Menarini. <i>Mahira El Sayed<\/i> is a speaker and advisory board member of AbbVie, Novartis, Janssen, Amgen, Sandoz, Sanofi, Pfizer, and Eli Lilly. <i>Pierre-Dominique Ghislain<\/i> is receiving consultancy and fees as speaker, investigator, or grants for Pfizer, MSD, AbbVie, Janssen, Serono, Leo, Novartis, UCB, Amgen, Eli Lilly, Galderma, BMS, Meda, Maruho, Flen, Menarini, Almirall, PellePharm, and Viatris. <i>Alkes A Khotko<\/i> is an investigator in sponsored clinical trials of AbbVie, Novartis, Janssen, Amgen, Sanofi, Eli Lilly, Biocad, Akrikhin, Alfasigma S.p.A., OOO Pharmapark, Argenx BV, and Bristol Myers Squibb. <i>Manmath Patekar<\/i>, <i>Christine-Elke Ortmann<\/i>, <i>Philemon Papanastasiou<\/i>, <i>Pascal Forrer<\/i>, and <i>Deborah Keefe<\/i> are employees of Novartis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The clinical trials were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice (GCP) and in compliance with all federal, local, or regional requirements.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"An informed consent form approved by a study site\u2019s institutional review board was signed by the participants or legal representative and the investigator before enrollment of participants.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"The datasets generated and\/or analyzed during the current study are not publicly available. Novartis is committed to sharing with qualified external researchers access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved on the basis of scientific merit. All data provided are anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The data may be requested from the corresponding author of the article.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Concept and design: MS, AFN, AMH, PK, JCS, MES, P-DG, AAK, MP, PP, PF, DK. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: All authors. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: C-EO. Administrative, supervision, technical, or material support: All authors.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}